CPO301-US-101 CPO301-US-101: A Phase 1, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO301, an EGFR-Targeting Antibody-Drug Conjugate, in Adult Patients with Adv

NCT05948865

CPO301-US-101: A Phase 1, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO301, an EGFR-Targeting Antibody-Drug Conjugate, in Adult Patients with Advanced or Metastatic Solid Tumors

Associated Conditions

Multiple Myeloma

Principal Investigator

Guru Sonpavde

Sponsor

Conjupro Biotherapeutics, Inc.

The purpose of the study, called CPO301-US-101, is to see if CPO301 (also known as SYS6010) is safe and effective in treating your type of cancer when administered as an intravenous (administered into the vein) infusion (IV) over 60 minutes.
The study will also: Assess the tolerability (body’s ability to handle) of the study drug, Monitor the amount of study drug in your body after administration and how quickly your body gets rid of it (pharmacokinetics), and Assess the ability of the study drug to create an immune response in the body (immunogenicity). The study treatment is CPO301, which is an investigational drug. “Investigational” means that the drug is being studied and has not been approved by US FDA (US Food and Drug Administration) or Health Canada (Health Products and Food Branch). CPO301 recognizes, binds, and kills the cancer-causing cells in the body.
CPO301 has not been tested in humans before.

This study is currently enrolling.